FLT3 and acute myeloid leukemia: As of January 2025 currently ongoing clinical trials on CAR-NK focus not only on CD19 target but also on CD123 clinical trials.gov; ID (NCT05574608) and clinical trials.gov; ID CLL-1(NCT06307054) in acute myeloid leukemia (AML) or dual targeting of CD19 and CD70 clinical trials.gov; ID (NCT05842707) in B cell Non-Hodgkin lymphoma and CD33 and/or FLT3 in AML clinical trials.gov; ID (NCT06325748).